Use of cdk9 inhibitors to reduce cartilage degradation

Abstract

The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.

1 - 28 . (canceled) 
     
     
         29 . A method of reducing or inhibiting inflammation of tissue in response to an inflammatory stimulus, comprising administering locally or intralesionally to a subject having a traumatic joint injury, a local inflammation, or a surgery an effective amount of a CDK9 inhibitor or salt thereof, wherein the administered CDK9 inhibitor suppresses an inflammatory response at or near the site of the traumatic joint injury, local inflammation, or surgery. 
     
     
         30 . The method of  claim 29 , wherein the CDK9 inhibitor or salt thereof suppresses an inflammatory response in a cell or tissue selected from the group consisting of cartilage, chondrocyte, joint, synovial cell, meniscal cell, ligament, and bone. 
     
     
         31 . The method of  claim 29 , wherein the inflammatory response is an acute inflammatory response. 
     
     
         32 . The method of  claim 29 , wherein the inflammatory response is activation of a catabolic pathway in a cell or tissue selected from the group consisting of cartilage, chondrocyte, joint, synovial cell, meniscal cell, ligament, and bone. 
     
     
         33 . The method of  claim 29 , further comprising reducing or inhibiting transcriptional activation of one or more primary response genes. 
     
     
         34 . The method of  claim 33 , wherein the primary response genes comprise one or more of IL-1β, IL-10, inducible nitric oxide synthase (iNOS), IL-6, TNFα, MMP-1, MMP-3, MMP-9, IL-1a, NFKB1, SOD2, CTSS, MMP-13, ADAMTS4 (aggrecanase), CDKN1A, F3, IL-15, ADM, FAS, CD83, EGFR, CFB, IL1RN, CXCL1, BCL2A1, IL-2, BIRC3, PTGS2, ICAM1, NFKB1A, NR4A2, RELA, CSF1, IL-8, TNFRSF1B, CCL5, RELB, VCAM1, REL, CCL2, CD40, CXCL9, CSF2, CXCL2, CSF3, and CXCL10. 
     
     
         35 . The method of  claim 33 , wherein the primary response genes comprise one or more of inducible nitric oxide synthase (iNOS), IL-6, SOD2, CTSS, NR4A2, RELA, RELB, and REL. 
     
     
         36 . The method of  claim 29 , further comprising reducing or inhibiting pain in the treated subject. 
     
     
         37 . The method of  claim 29 , wherein the CDK9 inhibitor or salt thereof is administered within about 10 days of injury. 
     
     
         38 . The method of  claim 29 , wherein the CDK9 inhibitor or salt thereof is administered within about 4 days of injury. 
     
     
         39 . The method of  claim 29 , wherein the CDK9 inhibitor or salt thereof is administered within about 3 days of injury. 
     
     
         40 . The method of  claim 29 , wherein the CDK9 inhibitor or salt thereof is administered within about 2 days of injury. 
     
     
         41 . The method of  claim 29 , wherein the CDK9 inhibitor or salt thereof is administered within about 1 day of injury. 
     
     
         42 . The method of  claim 29 , wherein the CDK9 inhibitor or salt thereof is administered within about 3 hours of injury. 
     
     
         43 . The method of  claim 29 , wherein the administration of CDK9 inhibitor or salt thereof reduces, delays, or inhibits future onset of osteoarthritis. 
     
     
         44 . The method of  claim 29 , wherein suppressing the inflammatory response comprises protecting tissue from the harmful effects of pro-inflammatory cytokines. 
     
     
         45 . The method of  claim 29 , wherein the CDK9 inhibitor or salt thereof is flavopiridol or a salt thereof. 
     
     
         46 . The method of  claim 29 , wherein the CDK9 inhibitor or salt thereof is selected from the group consisting of 4-(3,5-diamino-1H-pyrazol-4-ylazo)-phenol, 2-(pyridin-4-yl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridinone (PHA-767491), a biaryl compound, a pyridine biaryl amine compound; a pyrimidine biaryl amine compound; an N-acyl pyrimidine biaryl compound; an N-acyl pyridine biaryl compound; a 3-(aminoaryl)-pyridine compound; and a phenyl-heteroaryl amine. 
     
     
         47 . The method of  claim 29 , further comprising repeated or sustained administration of the CDK9 inhibitor or salt thereof. 
     
     
         48 . The method of  claim 29 , wherein the administration of the CDK9 inhibitor decreases pain, decreases swelling, increases joint mobility, or any combination thereof. 
     
     
         49 . A method for inhibiting the expression of a primary response gene in a cell, comprising treating the cell with an effective amount of a CDK9 inhibitor or a salt thereof. 
     
     
         50 . The method of  claim 50 , wherein the primary response gene is one or more of IL-1β, IL-10, inducible nitric oxide synthase (iNOS), IL-6, TNFα, MMP-1, MMP-3, MMP-9, IL-1a, NFKB1, SOD2, CTSS, MMP-13, ADAMTS4 (aggrecanase), CDKN1A, F3, IL-15, ADM, FAS, CD83, EGFR, CFB, IL1RN, CXCL1, BCL2A1, IL-2, BIRC3, PTGS2, ICAM1, NFKB1A, NR4A2, RELA, CSF1, IL-8, TNFRSF1B, CCL5, RELB, VCAM1, REL, CCL2, CD40, CXCL9, CSF2, CXCL2, CSF3, and CXCL10. 
     
     
         51 . The method of  claim 50 , wherein the primary response gene is one or more of inducible nitric oxide synthase (iNOS), IL-6, SOD2, CTSS, NR4A2, RELA, RELB, and REL. 
     
     
         52 . The method of  claim 52 , wherein the CDK9 inhibitor is flavopiridol or a salt thereof.